Eugene V. Genovesi - Concepedia

Author

Eugene V. Genovesi

Also Known As

E Genovesi, E V Genovesi, E. V. Genovesi, E.V Genovesi, E.V. Genovesi, Eugene V Genovesi, Eugene V. Genovesi, Eugene V. Genovesi, Genovesi, Eugene V.

Publications

913

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Plum Island Animal Disease Center Bristol-Myers Squibb (Germany)

About

Eugene V. Genovesi is an author at Bristol-Myers Squibb (United States) specializing in medicine, virology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	550
2	Immunology	10	10	313
3	Cell Biology	2	2	67
4	Allergy	1	1	13
5	Hepatology	1	1	118

Eugene V. Genovesi

Publications

826

Citations

H-Index

Page 1

	Year	Citations
Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection Richard J. Colonno, Eugene V. Genovesi, Ivette Medina, The Journal of Infectious Diseases	2001	141
Orally Active Fusion Inhibitor of Respiratory Syncytial Virus Christopher Cianci, Kuo‐Long Yu, Keith D. Combrink, Antimicrobial Agents and Chemotherapy	2004	135
Efficacy of the Carbocyclic 2′-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection Eugene V. Genovesi, L. Lamb, I Medina, Antimicrobial Agents and Chemotherapy Bms-200475 TherapyViral DiagnosticsHepatitis BPathologyAntiviral Drug	1998	118
Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection Christopher Cianci, Eugene V. Genovesi, Lucinda Lamb, Antimicrobial Agents and Chemotherapy ImmunologyOral EfficacyAntiviral DrugAntiviral Drug DevelopmentInfection Control	2004	77
Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability Kuo‐Long Yu, Ny Sin, Rita L. Civiello, Bioorganic & Medicinal Chemistry Letters Oral BioavailabilityMedicineAntiviral Drug DevelopmentAntiviral ResponseAntiviral Therapy	2006	68
Respiratory syncytial virus fusion inhibitors. Part 7: Structure–activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo Ny Sin, Brian L. Venables, Keith D. Combrink, Bioorganic & Medicinal Chemistry Letters Antiviral ActivityMedicineImmunologyAntiviral ResponseMolecular Biology	2009	44
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo Kuo‐Long Yu, Xiangdong Alan Wang, Rita L. Civiello, Bioorganic & Medicinal Chemistry Letters Water-soluble Benzimidazol-2-one DerivativesAntiviral ActivityMedicineImmunologyAntiviral Drug Development	2005	40
In vitro induction of swine peripheral blood monocyte proliferation by the fibroblast-derived murine hematopoietic growth factor CSF-1 Eugene V. Genovesi, Richard C. Knudsen, D.J. Gerstner, Veterinary Immunology and Immunopathology Regenerative MedicineVitro InductionStem Cell MobilizationHematologyImmunology	1989	40
Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety Keith D. Combrink, H. Belgin Gülgeze, Jan Willem Thuring, Bioorganic & Medicinal Chemistry Letters Virus StructureStructural VariationMedicineAntiviral Drug DevelopmentMolecular Biology	2007	37
Effect of macrophage-specific colony-stimulating factor (CSF-1) on swine monocyte/macrophage susceptibility to in vitro infection by African swine fever virus Eugene V. Genovesi, François Villinger, D.J. Gerstner, Veterinary Microbiology Vitro InfectionSwine Monocyte/macrophage SusceptibilityPathogenesisImmunologyViral Pathogenesis	1990	34

Page 1